Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 19 studies | 31% ± 11% | |
oligodendrocyte | 13 studies | 27% ± 12% | |
basal cell | 13 studies | 28% ± 10% | |
fibroblast | 11 studies | 22% ± 7% | |
glutamatergic neuron | 7 studies | 36% ± 18% | |
retinal rod cell | 6 studies | 25% ± 7% | |
endothelial cell | 5 studies | 21% ± 4% | |
retinal ganglion cell | 5 studies | 35% ± 16% | |
epithelial cell | 5 studies | 33% ± 6% | |
cardiac muscle cell | 5 studies | 49% ± 7% | |
connective tissue cell | 5 studies | 29% ± 9% | |
goblet cell | 5 studies | 22% ± 10% | |
squamous epithelial cell | 4 studies | 51% ± 18% | |
brush cell | 4 studies | 39% ± 11% | |
Mueller cell | 4 studies | 27% ± 7% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 4 studies | 17% ± 1% | |
luminal cell of prostate epithelium | 4 studies | 22% ± 6% | |
pericyte | 4 studies | 28% ± 7% | |
myoepithelial cell | 4 studies | 59% ± 16% | |
ionocyte | 3 studies | 37% ± 6% | |
T follicular helper cell | 3 studies | 22% ± 5% | |
myofibroblast cell | 3 studies | 31% ± 11% | |
adipocyte | 3 studies | 28% ± 13% | |
astrocyte | 3 studies | 22% ± 5% | |
muscle cell | 3 studies | 58% ± 26% | |
GABAergic neuron | 3 studies | 30% ± 3% | |
secretory cell | 3 studies | 26% ± 10% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 91% | 10094.32 | 222 / 245 | 99% | 49.36 | 499 / 502 |
uterus | 93% | 23803.03 | 158 / 170 | 84% | 44.24 | 384 / 459 |
esophagus | 79% | 15531.49 | 1148 / 1445 | 92% | 39.10 | 168 / 183 |
ovary | 82% | 8245.22 | 147 / 180 | 89% | 38.71 | 381 / 430 |
breast | 68% | 9116.21 | 310 / 459 | 99% | 71.85 | 1108 / 1118 |
intestine | 87% | 29140.55 | 841 / 966 | 76% | 19.32 | 403 / 527 |
bladder | 81% | 24996.00 | 17 / 21 | 77% | 24.78 | 386 / 504 |
skin | 49% | 2839.07 | 883 / 1809 | 99% | 60.04 | 466 / 472 |
stomach | 37% | 9750.92 | 134 / 359 | 75% | 25.19 | 214 / 286 |
brain | 13% | 846.94 | 337 / 2642 | 97% | 51.21 | 681 / 705 |
thymus | 11% | 553.92 | 69 / 653 | 92% | 24.34 | 556 / 605 |
muscle | 100% | 129776.61 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.65 | 1 / 1 |
blood vessel | 99% | 30636.24 | 1316 / 1335 | 0% | 0 | 0 / 0 |
lung | 5% | 275.36 | 30 / 578 | 93% | 33.90 | 1069 / 1155 |
pancreas | 2% | 90.36 | 7 / 328 | 95% | 46.83 | 169 / 178 |
tonsil | 0% | 0 | 0 / 0 | 93% | 33.39 | 42 / 45 |
eye | 0% | 0 | 0 / 0 | 84% | 26.26 | 67 / 80 |
heart | 81% | 8469.54 | 694 / 861 | 0% | 0 | 0 / 0 |
kidney | 2% | 97.22 | 2 / 89 | 55% | 9.65 | 495 / 901 |
adipose | 33% | 2059.42 | 392 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 4.00 | 8 / 29 |
adrenal gland | 2% | 121.29 | 6 / 258 | 19% | 4.30 | 43 / 230 |
liver | 0% | 0 | 0 / 226 | 17% | 3.26 | 67 / 406 |
spleen | 5% | 176.91 | 11 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 53.56 | 4 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0014894 | Biological process | response to denervation involved in regulation of muscle adaptation |
GO_0016567 | Biological process | protein ubiquitination |
GO_0071549 | Biological process | cellular response to dexamethasone stimulus |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0030018 | Cellular component | Z disc |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXO32 |
Protein name | F-box only protein 32 (Atrogin-1) (Muscle atrophy F-box protein) (MAFbx) F-box only protein 32 |
Synonyms | |
Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins during skeletal muscle atrophy. Recognizes TERF1. . FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins during skeletal muscle atrophy. Recognizes TERF1. . FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins during skeletal muscle atrophy. Recognizes TERF1. . FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins during skeletal muscle atrophy. Recognizes TERF1. . |
Accessions | ENST00000517956.5 [Q969P5-1] ENST00000443022.2 [Q969P5-2] I6L984 Q0VAQ6 Q498Y9 Q969P5 |